资讯
Boston— Allarity Therapeutics, Inc., a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib— a differentiated dual PARP/Wnt pathway inhibitor— announced the ...
Data to be presented at the ASGCT Annual Meeting include an oral presentation from Sangamo’s flagship neurology epigenetic regulation program Nav1.7 to treat chronic neuropathic pain.
Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeting 2021.
Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of ...
Data featured in oral presentation and poster session at 48th European Cystic Fibrosis Conference WALTHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a ...
7 小时
TipRanks on MSNGH Research Presents Promising Trial Results for GH001 at ISBD 2025
GH Research ( ($GHRS) ) has issued an update. GH Research PLC announced the presentation of data from its GH001-BD-202 clinical trial at the ...
Inconsistencies in data presentation could harm efforts against COVID-19 New research shows broad array of different content, formats in data available on national public health institutes ...
Perspective Therapeutics Announces Acceptance of Key Radiopharmaceutical Data for Presentation at ASCO 2025 Annual Meeting April 23, 2025 — 12:30 pm EDT Written by None for Quiver Quantitative -> ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果